Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Tampere – page 20

276 clinical trials in Tampere, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Tampere at a glance
276
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

276 trials in Tampere

Open in trial search

Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Bladder cancer

Not recruiting

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Tampere

What the registry says about research in the country

01 Infectious Disease Prevention

Extensive research focusing on vaccine development against multiple viral infections, including influenza, RSV, and meningococcal disease. Clinical trials are evaluating novel immunization strategies for different age groups.

  • Influenza vaccine trials for adults 60+
  • RSV prevention in infants and elderly
  • Meningococcal vaccines for children

Multiple studies are investigating immune responses and long-term protection against respiratory infections.

02 Oncology Research

Innovative trials exploring new treatments for various cancers, with emphasis on advanced solid tumors and blood cancers. Studies combine novel therapeutic approaches with existing treatments.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Focus on developing targeted therapies and improving treatment outcomes for cancer patients.

03 Diagnostic Medicine

Research evaluating advanced diagnostic techniques, particularly in emergency medicine and acute conditions. Studies compare different imaging methods and their effectiveness.

  • CT scanning protocols
  • Emergency diagnostics
  • Treatment response monitoring

Emphasis on improving diagnostic accuracy while considering patient safety.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.